Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Shaygannejad

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Neurology|December 13, 2007
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosisM Etemadifar, M Janghorbani, V Shaygannejad
Acta Neurologica Scandinavica|April 25, 2006
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosisM Etemadifar, M Janghorbani, V Shaygannejad
Acta Neurologica Scandinavica|August 21, 2008
A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxisF Ashtari, V Shaygannejad, M Akbari
Neurologia|September 2, 2022
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysisO Mirmosayyeb, V Shaygannejad, N Ebrahimi, et al.
Neurologia|August 13, 2022
The prevalence of sexual dysfunction and erectile dysfunction in men with multiple sclerosis: A systematic review and meta-analysisV Shaygannejad, O Mirmosayyeb, S Vaheb, et al.
Revue Neurologique|January 19, 2023
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic reviewO Mirmosayyeb, E M Ghaffary, S Vaheb, et al.
Multiple Sclerosis and Related Disorders|May 7, 2018
Phase sensitive reconstruction of T1-weighted inversion recovery in the evaluation of the cervical cord lesions in Multiple Sclerosis; is it similarly eligible in 1.5 T magnet fields?A Shayganfar, A H Sarrami, S Fathi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Conjugal multiple sclerosis in Isfahan, Iran: a population-based studyA H Maghzi, M Etemadifar, V Shaygannejad, et al.
Journal of Neurology|January 13, 2019
Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective studyV Shaygannejad, E Fayyazi, S Badihian, et al.
Journal of Biological Regulators and Homeostatic Agents|October 19, 2018
Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progressionS Badihian, V Shaygannejad, P Soleimani, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Neurology|December 13, 2007
Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosisM Etemadifar, M Janghorbani, V Shaygannejad
Acta Neurologica Scandinavica|April 25, 2006
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosisM Etemadifar, M Janghorbani, V Shaygannejad
Acta Neurologica Scandinavica|August 21, 2008
A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxisF Ashtari, V Shaygannejad, M Akbari
Neurologia|September 2, 2022
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysisO Mirmosayyeb, V Shaygannejad, N Ebrahimi, et al.
Neurologia|August 13, 2022
The prevalence of sexual dysfunction and erectile dysfunction in men with multiple sclerosis: A systematic review and meta-analysisV Shaygannejad, O Mirmosayyeb, S Vaheb, et al.
Revue Neurologique|January 19, 2023
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic reviewO Mirmosayyeb, E M Ghaffary, S Vaheb, et al.
Multiple Sclerosis and Related Disorders|May 7, 2018
Phase sensitive reconstruction of T1-weighted inversion recovery in the evaluation of the cervical cord lesions in Multiple Sclerosis; is it similarly eligible in 1.5 T magnet fields?A Shayganfar, A H Sarrami, S Fathi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 6, 2007
Conjugal multiple sclerosis in Isfahan, Iran: a population-based studyA H Maghzi, M Etemadifar, V Shaygannejad, et al.
Journal of Neurology|January 13, 2019
Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective studyV Shaygannejad, E Fayyazi, S Badihian, et al.
Journal of Biological Regulators and Homeostatic Agents|October 19, 2018
Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progressionS Badihian, V Shaygannejad, P Soleimani, et al.
Pageof 2